Literature DB >> 12709339

Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001.

James A Karlowsky1, Mark E Jones, Clyde Thornsberry, Ian R Friedland, Daniel F Sahm.   

Abstract

Longitudinal surveillance of Enterobacteriaceae for antimicrobial susceptibility is important because species of this family are among the most significant and prevalent human pathogens. To estimate rates of in vitro antimicrobial susceptibility among hospitalized patients in the United States, data from The Surveillance Network were studied for 14 agents tested against 10 species of Enterobacteriaceae (n = 384,279) isolated from intensive-care-unit (ICU) patients and non-ICU inpatients from 1998 to 2001. Cumulative susceptibility (percent) data for all species of Enterobacteriaceae isolated from ICU patients and non-ICU inpatients, respectively, were ranked as follows: ampicillin-sulbactam (45.5 and 57.2) << ticarcillin-clavulanate (74.8 and 83.5) < trimethoprim-sulfamethoxazole (87.0 and 84.5) congruent with cefotaxime (82.9 and 92.6) = ceftazidime (82.3 and 91.0) = ceftriaxone (86.5 and 93.9) = piperacillin-tazobactam (83.5 and 90.5) < levofloxacin (89.3 and 90.6) = ciprofloxacin (91.0 and 91.7) < gentamicin (91.8 and 94.3) < cefepime (95.0 and 97.9) < amikacin (98.5 and 99.2) < imipenem (100 and 100) = meropenem (100 and 100). Of those agents studied only susceptibilities to ciprofloxacin (94 to 89%) and levofloxacin (93 to 89%) decreased in a stepwise manner from 1998 to 2001. Decreased fluoroquinolone susceptibility was most pronounced for Escherichia coli, Proteus mirabilis, and Enterobacter cloacae. For all species of Enterobacteriaceae, trimethoprim-sulfamethoxazole resistance was more commonly observed in isolates with a single-drug resistance phenotype while gentamicin and fluoroquinolone resistances were more common in isolates resistant to at least one additional class of antimicrobial agent. Ongoing surveillance of Enterobacteriaceae will be particularly important to monitor changes in fluoroquinolone susceptibility, as well as changes in the prevalence of isolates resistant to multiple classes of antimicrobial agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12709339      PMCID: PMC153325          DOI: 10.1128/AAC.47.5.1672-1680.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus.

Authors:  H M Blumberg; D Rimland; D J Carroll; P Terry; I K Wachsmuth
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

Review 2.  Consequences of increasing resistance to antimicrobial agents.

Authors:  J F Acar; F W Goldstein
Journal:  Clin Infect Dis       Date:  1998-08       Impact factor: 9.079

3.  Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition.

Authors:  J C Lucet; S Chevret; D Decré; D Vanjak; A Macrez; J P Bédos; M Wolff; B Regnier
Journal:  Clin Infect Dis       Date:  1996-03       Impact factor: 9.079

4.  The value of routine microbial investigation in ventilator-associated pneumonia.

Authors:  J Rello; M Gallego; D Mariscal; R Soñora; J Valles
Journal:  Am J Respir Crit Care Med       Date:  1997-07       Impact factor: 21.405

Review 5.  A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Authors:  K Bush; G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

Review 6.  beta-Lactamases in laboratory and clinical resistance.

Authors:  D M Livermore
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

7.  Comparative activity of cefoxitin, ampicillin/sulbactam, and imipenem against clinical isolates of Escherichia coli and Klebsiella pneumoniae.

Authors:  D L Shungu; S Ponticas; C J Gill
Journal:  Clin Ther       Date:  1989 May-Jun       Impact factor: 3.393

8.  Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections.

Authors:  C Peña; J M Albareda; R Pallares; M Pujol; F Tubau; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

9.  Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins.

Authors:  K S Meyer; C Urban; J A Eagan; B J Berger; J J Rahal
Journal:  Ann Intern Med       Date:  1993-09-01       Impact factor: 25.391

10.  Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals.

Authors:  Scott K Fridkin; Holly A Hill; Nataliya V Volkova; Jonathan R Edwards; Rachel M Lawton; Robert P Gaynes; John E McGowan
Journal:  Emerg Infect Dis       Date:  2002-07       Impact factor: 6.883

View more
  24 in total

1.  In vivo acquisition of high-level resistance to imipenem in Escherichia coli.

Authors:  Laurent Poirel; Claire Héritier; Colette Spicq; Patrice Nordmann
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

2.  Recovery of Gram-negative bacilli in stored endotracheal aspirates.

Authors:  Tarah D Ranke; Paula Strassle; Anthony D Harris; Jingkun Zhu; J Kristie Johnson
Journal:  J Clin Microbiol       Date:  2012-05-30       Impact factor: 5.948

3.  Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center.

Authors:  Neil Woodford; Philip M Tierno; Katherine Young; Luke Tysall; Marie-France I Palepou; Elaina Ward; Ronald E Painter; Deborah F Suber; Daniel Shungu; Lynn L Silver; Kenneth Inglima; John Kornblum; David M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  Test characteristics of perirectal and rectal swab compared to stool sample for detection of fluoroquinolone-resistant Escherichia coli in the gastrointestinal tract.

Authors:  Ebbing Lautenbach; Anthony D Harris; Eli N Perencevich; Irving Nachamkin; Pam Tolomeo; Joshua P Metlay
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

5.  Co-colonization with multiple different species of multidrug-resistant gram-negative bacteria.

Authors:  Graham M Snyder; Erin O'Fallon; Erika M C D'Agata
Journal:  Am J Infect Control       Date:  2011-04-13       Impact factor: 2.918

6.  Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004.

Authors:  Shawn R Lockhart; Murray A Abramson; Susan E Beekmann; Gale Gallagher; Stefan Riedel; Daniel J Diekema; John P Quinn; Gary V Doern
Journal:  J Clin Microbiol       Date:  2007-08-22       Impact factor: 5.948

Review 7.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Multidrug resistance and plasmid patterns of Escherichia coli O157 and other E. coli Isolated from diarrhoeal stools and surface waters from some selected sources in Zaria, Nigeria.

Authors:  Vincent N Chigor; Veronica J Umoh; Stella I Smith; Etinosa O Igbinosa; Anthony I Okoh
Journal:  Int J Environ Res Public Health       Date:  2010-10-25       Impact factor: 3.390

9.  Correlation between antibiotic use and resistance in a hospital: temporary and ward-specific observations.

Authors:  I Willemsen; D Bogaers-Hofman; M Winters; J Kluytmans
Journal:  Infection       Date:  2009-06-04       Impact factor: 3.553

10.  Inhibition of aminoglycoside 6'-N-acetyltransferase type Ib-mediated amikacin resistance by antisense oligodeoxynucleotides.

Authors:  Renee Sarno; Hongphuc Ha; Natalia Weinsetel; Marcelo E Tolmasky
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.